DiaCarta Clinical Services Laboratory Receives CLIA Certification
DiaCarta Inc. today announced that DiaCarta Clinical Services Laboratory (DCSL) successfully passed the State of California survey under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The State of California inspector gave DCSL permission to begin offering QClamp-based molecular diagnostic patient and clinical trial testing services.
The DiaCarta-owned and -operated laboratories, both in Richmond, California, and Nanjing, China, enable clinical and research laboratories, as well as diagnostic and pharmaceutical companies, to incorporate complex molecular tests into clinical practice. The CLIA certification ensures that all of its processes are standardized to consistently meet federal and Clinical Laboratory Standards Institute (CLSI) guidelines for accuracy, precision, sensitivity, calibration and control. In addition, all of the DCSL assays have been validated for clinical applications to ensure reproducible results.
Located in Richmond, California, DCSL is a facility of over 16,000 square feet. The laboratory specializes in patient testing and clinical trial services for gene mutation and gene expression monitoring, genotyping and copy number analysis, as well as other molecular diagnostic tests. The company is dedicated to the science of rapid, highly sensitive detection technologies and diagnostic solutions for healthcare that positively impact treatment plans and improve the wellbeing of individuals around the world. QClamp®, a revolutionary new way to screen for somatic mutations in cancer genes, utilizes a sequence-specific xeno-nucleic acid (XNA) clamp that suppresses PCR amplification on wild-type DNA template and allows selective amplification of only mutant template. With its detection sensitivity below 0.1%, QClamp® is ideal for a variety of samples including FFPE tissue, liquid biopsy and traditionally challenging cytology specimens. QClamp® on next-generation sequencing (NGS), the OptiSeq™ platform, can implement mutant DNA target enrichment to detect very low copy mutant numbers that are not possible by conventional NGS protocols.
“We are very excited about the new addition of CLIA-certified clinical laboratory testing to our suite of product offerings. Our CLIA certification is an important regulatory milestone and demonstrates our commitment to quality laboratory testing to provide accurate, reliable and timely test results,” said Dr. Aiguo Zhang, Founder and CEO of DiaCarta. “With our Independent Clinical Service Lab also in Nanjing, China, we are well positioned to become a key companion diagnostic partner with pharmaceutical companies for global clinical trials of novel targeted therapies.”
About DiaCarta Inc.
DiaCarta is a translational genomics and personalized diagnostics company headquartered in Richmond, California with business and clinical operations in Shanghai and Nanjing, China, respectively. We are dedicated to the science of rapid and highly sensitive detection technologies and diagnostic solutions for healthcare that positively impact treatment plans and improve the well-being of individuals around the world. QClamp®, a revolutionary new way to screen for tumor oncogenic driver and resistance mutations in tumor DNA derived from cancer patients, utilizes a sequence-specific xeno-nucleic acid (XNA) clamp that suppresses PCR amplification on wild-type DNA template and allows selective amplification of only mutant template with detection sensitivity below 0.1% for a variety of samples including FFPE tissue, liquid biopsy and traditionally challenging cytology specimens. The QClamp® XNA-PCR technology has also been applied for mutant DNA target enrichment on our OptiSeq™ next-generation sequencing platform. QuantiVirus™ HPV cervical cancer and DigiPlex™ genotyping tests are the products powered by SuperbDNA™ and multiplex bar-coding technology platforms, respectively. To learn more, visit https://www.diacarta.com.
DiaCarta Helps Communities Scale Up Their MPOX Testing Efforts with Its Simple, Reliable, and FDA-EUA-Approved MPOX Testing Kits
DiaCarta, Inc., an experienced in-vitro diagnostics (IVD) company that provided COVID-19 testing kits during the global pandemic, has expanded its focus to mpox detection and the detection of other infectious diseases.
DiaCarta and Capstone Health Alliance Collaborate to Bring Revolutionary Diagnostic Tests to Enhance Patient Care
DiaCarta, Inc., a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic collaboration with Capstone Health Alliance, one of the largest regional group purchasing organizations (GPO) in the US healthcare sector. This new collaboration brings together powerful technologies to enhance patient care.
Florida Selects DiaCarta’s cfDNA Test (RadTox™) for Statewide Use to Detect Early Response of Cancer Treatment
DiaCarta, a leading molecular diagnostics company specializing in personalized patient care through liquid biopsy, proudly announced that Florida Health Department selected “using plasma DNA concentration (DiaCarta’s RadTox™ test) for early detection of treatment response and resistance” through the Casey DeSantis Florida Cancer Innovation Fund. This fund supports deployment of the RadTox™ test throughout the State of Florida to be performed between Radiotherapy or Chemotherapy doses for real time detection of treatment response or resistance. The results will be as a real time predictor of imaging data.
DiaCarta Announces That the Oncuria® Bladder Cancer Tests Receive Medicare Coverage Effective January 1, 2024
DiaCarta proudly announced that the Oncuria® Bladder Cancer Tests, developed by Nonagen Bioscience and validated by DiaCarta as a Lab Developed Test (LDT), at its CAP-accredited and CLIA-certified laboratory, have received Medicare coverage effective January 1, 2024.
DiaCarta, Inc. and OncoAssure Ltd. Collaborate to Launch Prostate Cancer Lab Developed Test
DiaCarta, Inc. (“DiaCarta”), a pioneer in molecular diagnostic test development for cancer and infectious diseases, today announced that it has established a strategic collaboration with OncoAssure Ltd, an Irish medical diagnostics company. The focus of the collaboration is to commercialize OncoAssure’s groundbreaking Prostate test which is designed to identify patients with a lower risk of prostate cancer recurrence, guiding decisions on active surveillance or reduced monitoring post-treatment.